Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) EBITDA Margin (2018 - 2025)

Precision Biosciences (DTIL) has disclosed EBITDA Margin for 8 consecutive years, with 158976.92% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 15528335.0% to 158976.92% in Q3 2025 year-over-year; TTM through Sep 2025 was 12822.64%, a 1280106.0% decrease, with the full-year FY2024 number at 38.08%, up 5167.0% from a year prior.
  • EBITDA Margin was 158976.92% for Q3 2025 at Precision Biosciences, down from 121538.89% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 165.78% in Q4 2022 to a low of 158976.92% in Q3 2025.
  • A 5-year average of 19318.33% and a median of 199.32% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 307485bps in 2021, then crashed -15528335bps in 2025.
  • Precision Biosciences' EBITDA Margin stood at 484.68% in 2021, then surged by 134bps to 165.78% in 2022, then plummeted by -228bps to 211.57% in 2023, then crashed by -1741bps to 3894.36% in 2024, then tumbled by -3982bps to 158976.92% in 2025.
  • Per Business Quant, the three most recent readings for DTIL's EBITDA Margin are 158976.92% (Q3 2025), 121538.89% (Q2 2025), and 76248.28% (Q1 2025).